並列摘要
Venous thromboembolism is a major source of morbidity and mortality for gynecologic oncology patients. This increased risk for pelvic surgery patients is secondary to emboli that can arise from the lower extremities as well as the pelvic veins. Furthermore, as cancer is a heterogeneous disease, the risk of venous thrombosis depends on cancer types and stages, treatment measures, and patient-related factors. Because venous thromboembolism can begin intraoperatively, preoperative administration of pharmacologic prophylaxis is likely beneficial without significant harms for gynecologic oncology patients. However, optimal anticoagulation in such instances presents a major challenge to gynecologic oncologist.